Alchemab Therapeutics announces that Jane Osbourn, Chief Scientific Officer, has succeeded Young Kwon as Chief Executive Officer and member of the Board. Jane Osbourn has more than 30 years of biopharmaceutical industry experience and has been a key leader in the company since its inception.
Who to call at Alchemab Therapeutics, and when
A new leader at Alchemab Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alchemab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alchemab Therapeutics
Location
London, England, United Kingdom
About
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alchemab Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LondonBiotechnologyHealth CareTherapeuticsPharmaceutical